Method for the treatment of obesity
View Patent ↗The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject using immunotherapy to target and eliminate adipocytes.
1. A method of eliminating adipocytes in a subject, comprising administering a therapeutically effective amount of a composition comprising isolated T lymphocytes modified to express a target specific chimeric antigen receptor, wherein the target is a cell surface antigen preferentially expressed on an adipocyte.
2. The method of claim 1 , wherein the isolated T lymphocytes modified to express a target specific chimeric antigen receptor are endogenous T lymphocytes from the subject.
3. The method of claim 1 , wherein the target is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) or AD3.
4. The method of claim 1 , wherein the T lymphocytes are naïve cells, central memory cells, effector memory cells, or any combination thereof.
5. The method of claim 4 , wherein the T lymphocytes are naive cells having a phenotype of CD28+ CD62L+ CD95− and CD45RA+.
6. The method of claim 4 , wherein the T lymphocytes are central memory cells having a phenotype of CD28+ CD62L+ CD95+ and CD45RA−.
7. The method of claim 4 , wherein the T lymphocytes are effector memory cells having a phenotype of CD28− CD62L− and CD45RA−.
8. The method of claim 4 , wherein the T lymphocytes are CD4+, CD8+, or a mixture thereof.
9. The method of claim 8 , wherein the T lymphocytes are human.
10. The method of claim 1 , wherein the subject is obese or at risk for obesity.
11. The method of claim 1 , wherein the subject has an obesity related disorder selected from cardiovascular disease, endocrine disease, musculoskeletal disorder, diabetes, or any combination thereof.
12. The method of claim 1 , wherein the subject is a human.
13. The method of claim 1 , wherein the T lymphocytes are CD4+, CD8+, or a mixture thereof.